Home›Olmesartan Medoxomil

Olmesartan Medoxomil

Also known as: Olmesartan Medoxomil

Route: Oral

Check Olmesartan Medoxomil Interactions →

17 interactions on record⛔ Black Box Warning

Olmesartan Medoxomil has 17 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 10 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Aliskiren, Amiloride, Colesevelam Hydrochloride. Patients taking Olmesartan Medoxomil should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 17
Contraindicated: 1
Major: 10
Moderate: 2
Minor: 4

Contraindicated (1)

Olmesartan Medoxomil + Aliskiren— Co-administration contraindicated in patients with diabetes. Avoid in patients with renal impairment (GFR <60 ml/min). A…

Major (10)

Olmesartan Medoxomil + Amiloride— Potassium-sparing diuretic may lead to increases in serum potassium. Monitoring of serum potassium is advisable.
Olmesartan Medoxomil + Colesevelam Hydrochloride— Colesevelam may decrease olmesartan medoxomil exposure. Administer olmesartan medoxomil 4 hours prior to colesevelam.
Olmesartan Medoxomil + Heparin— May increase potassium levels and lead to increases in serum potassium. Monitoring of serum potassium is advisable.
Olmesartan Medoxomil + Ibuprofen— NSAIDs may result in deterioration of renal function, acute renal failure, and attenuated antihypertensive effect in eld…
Olmesartan Medoxomil + Lithium— Increases in serum lithium concentrations and lithium toxicity reported during concomitant administration with olmesarta…
Olmesartan Medoxomil + Mao Inhibitors— Co-administration may result in deterioration of renal function including possible acute renal failure, especially in el…
Olmesartan Medoxomil + Nsaids— Co-administration may result in deterioration of renal function including possible acute renal failure, especially in el…
Olmesartan Medoxomil + Potassium Supplements— May lead to increases in serum potassium. Monitoring of serum potassium is advisable.
Olmesartan Medoxomil + Spironolactone— Potassium-sparing diuretic may lead to increases in serum potassium. Monitoring of serum potassium is advisable.
Olmesartan Medoxomil + Triamterene— Potassium-sparing diuretic may lead to increases in serum potassium. Monitoring of serum potassium is advisable.

Moderate (2)

Olmesartan Medoxomil + Colesevelam— Colesevelam may decrease exposure of olmesartan medoxomil. Administer at least 4 hours prior to colesevelam.
Olmesartan Medoxomil + Olmesartan— 7.1 Agents Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin s…

Minor (4)

Olmesartan Medoxomil + Aluminum & Magnesium Hydroxides— Bioavailability of olmesartan was not significantly altered by co-administration of antacids.
Olmesartan Medoxomil + Antacids Containing Calcium— Bioavailability of olmesartan was not significantly altered by co-administration of aluminum hydroxide/magnesium hydroxi…
Olmesartan Medoxomil + Digoxin— No significant drug interactions reported when co-administered with olmesartan medoxomil in healthy volunteers.
Olmesartan Medoxomil + Warfarin— No significant drug interactions reported when co-administered with olmesartan medoxomil in healthy volunteers.

Olmesartan Medoxomil + Aliskiren⛔Contraindicated

Co-administration contraindicated in patients with diabetes. Avoid in patients with renal impairment (GFR <60 ml/min). Associated with increased risks of hypotension, hyperkalemia, and acute renal failure.

Olmesartan Medoxomil + Amiloride⚠️Major

Potassium-sparing diuretic may lead to increases in serum potassium. Monitoring of serum potassium is advisable.

Olmesartan Medoxomil + Colesevelam Hydrochloride⚠️Major

Colesevelam may decrease olmesartan medoxomil exposure. Administer olmesartan medoxomil 4 hours prior to colesevelam.

Olmesartan Medoxomil + Heparin⚠️Major

May increase potassium levels and lead to increases in serum potassium. Monitoring of serum potassium is advisable.

Olmesartan Medoxomil + Ibuprofen⚠️Major

NSAIDs may result in deterioration of renal function, acute renal failure, and attenuated antihypertensive effect in elderly, volume-depleted, or renal-impaired patients.

Olmesartan Medoxomil + Lithium⚠️Major

Increases in serum lithium concentrations and lithium toxicity reported during concomitant administration with olmesartan medoxomil. Monitor serum lithium levels.

Olmesartan Medoxomil + Mao Inhibitors⚠️Major

Co-administration may result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renally impaired patients. Antihypertensive effect may be attenuated.

Olmesartan Medoxomil + Nsaids⚠️Major

Olmesartan Medoxomil + Potassium Supplements⚠️Major

May lead to increases in serum potassium. Monitoring of serum potassium is advisable.

Olmesartan Medoxomil + Spironolactone⚠️Major

Potassium-sparing diuretic may lead to increases in serum potassium. Monitoring of serum potassium is advisable.

Olmesartan Medoxomil + Triamterene⚠️Major

Potassium-sparing diuretic may lead to increases in serum potassium. Monitoring of serum potassium is advisable.

Olmesartan Medoxomil + Colesevelam🟡Moderate

Colesevelam may decrease exposure of olmesartan medoxomil. Administer at least 4 hours prior to colesevelam.

Olmesartan Medoxomil + Olmesartan🟡Moderate

7.1 Agents Increasing Serum Potassium Concomitant use of olmesartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium. 7.2 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including olmesartan medoxomil, may result in deterioration of renal function, including possible acute renal failure. Monitor renal function periodically in patients receiving olmesartan medoxomil and NSAID therapy.

Olmesartan Medoxomil + Aluminum & Magnesium Hydroxides🟢Minor

Bioavailability of olmesartan was not significantly altered by co-administration of antacids.

Olmesartan Medoxomil + Antacids Containing Calcium🟢Minor

Bioavailability of olmesartan was not significantly altered by co-administration of aluminum hydroxide/magnesium hydroxide.

Olmesartan Medoxomil + Digoxin🟢Minor

No significant drug interactions reported when co-administered with olmesartan medoxomil in healthy volunteers.

Olmesartan Medoxomil + Warfarin🟢Minor

No significant drug interactions reported when co-administered with olmesartan medoxomil in healthy volunteers.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.